EVENITY® (romosozumab) receives positive CHMP Opinion for treatment of severe osteoporosis
Amgen announced that following a re-examination procedure, CHMP of the EMA has adopted a positive opinion recommending Marketing Authorization for EVENITY® (romosozumab) for treatment of severe osteoporosis in postmenopausal women at high risk of fracture. October 18, 2019